TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in…

RT @drpatrickholmes: #EASD2021 #type2diabetes #PrecisionMedicine TriMaster Trial 📍Study design paper👉https://t.co/eWfNtA9kx0 📍Testing 2…

RT @cardiomet_CE: TriMaster Trial 📍Study design paper👉https://t.co/kSf9uXry77 📍 Testing two hypothesis (after metformin+/-SU) ▶️1) BMI mo…

TriMaster Trial 📍Study design paper👉https://t.co/kSf9uXry77 📍 Testing two hypothesis (after metformin+/-SU) ▶️1) BMI modifies TZD Rx response ▶️2) eGFR modifies SGLT2i Rx response 📍both compared to a DPP4i 📍3-way crossover study design https://t.…

RT @PracticalDeeb: drpatrickholmes https://t.co/GlEcxRooZ3 #EASD2021 #dedoc°

drpatrickholmes https://t.co/GlEcxRooZ3 #EASD2021 #dedoc°

RT @drpatrickholmes: #EASD2021 #type2diabetes #PrecisionMedicine TriMaster Trial 📍Study design paper👉https://t.co/eWfNtA9kx0 📍Testing 2…

RT @Aldibbiat: Absolutely amazing summary and great tweet, 🎩 off to a great friend @drpatrickholmes

RT @drpatrickholmes: Sort of “what’s next after Metformin “? @AmarPut @Amandaepps123 @redGDPS @drkevinfernando @ClareHambling @DeanEggitt @…

RT @AmarPut: One of the main trials being presented at #EASD2021 now - the TriMASTER study - if you’re unclear, have a look at the rational…

RT @Aldibbiat: Absolutely amazing summary and great tweet, 🎩 off to a great friend @drpatrickholmes

@RishiKanapathi1 @DesighenY @drdanidixon

Absolutely amazing summary and great tweet, 🎩 off to a great friend @drpatrickholmes

RT @drpatrickholmes: Sort of “what’s next after Metformin “? @AmarPut @Amandaepps123 @redGDPS @drkevinfernando @ClareHambling @DeanEggitt @…

RT @drpatrickholmes: #EASD2021 #type2diabetes #PrecisionMedicine TriMaster Trial 📍Study design paper👉https://t.co/eWfNtA9kx0 📍Testing 2…

RT @drpatrickholmes: Sort of “what’s next after Metformin “? @AmarPut @Amandaepps123 @redGDPS @drkevinfernando @ClareHambling @DeanEggitt @…

RT @drpatrickholmes: #EASD2021 #type2diabetes #PrecisionMedicine TriMaster Trial 📍Study design paper👉https://t.co/eWfNtA9kx0 📍Testing 2…

RT @drpatrickholmes: Sort of “what’s next after Metformin “? @AmarPut @Amandaepps123 @redGDPS @drkevinfernando @ClareHambling @DeanEggitt @…

Sort of “what’s next after Metformin “? @AmarPut @Amandaepps123 @redGDPS @drkevinfernando @ClareHambling @DeanEggitt @HPILLminster @Paddy_English

RT @drpatrickholmes: #EASD2021 #type2diabetes #PrecisionMedicine TriMaster Trial 📍Study design paper👉https://t.co/eWfNtA9kx0 📍Testing 2…

#EASD2021 #type2diabetes #PrecisionMedicine TriMaster Trial 📍Study design paper👉https://t.co/eWfNtA9kx0 📍Testing 2 hypothesis (after metformin+/-SU) ▶️1) BMI modifies TZD Rx response ▶️2) eGFR modifies SGLT2i Rx response 📍both compared to a DPP4i…

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in type 2 diabetes who have suboptimal glycaemic control on metformin treatment #EASD2021 @BMJ_Open https:…

RT @AmarPut: One of the main trials being presented at #EASD2021 now - the TriMASTER study - if you’re unclear, have a look at the rational…

One of the main trials being presented at #EASD2021 now - the TriMASTER study - if you’re unclear, have a look at the rationale and design before the main results presentation @GoggleDocs @EASDnews @BrJCardiol @UKCPADiabetes @youngdiab @DSNforumUK https:/…

@MiriamETucker @drsarahjdavies @AliRacaniere @sotonDSN @WilmotEmma @Amandaepps123 @SDelprato @pcdsociety @drrizwanhussain @DSNforumUK @UKCPADiabetes @youngdiab @CristobMorales @AliceYYCheng @drshafikuchay @HannahBeba Part of the trial design and questio…

RT @cardiomet_CE: https://t.co/0J9ocCfaIH

https://t.co/0J9ocCfaIH

@Paddy_English @GoggleDocs @AmarPut @drkevinfernando @redGDPS @DSNforumUK @HannahBeba @SouthAsianHF @AliceYYCheng @AbdTahrani Ah those clever folks down in Exeter always have things covered! @angusgjones @athattersley @john_den_ https://t.co/51dtjttHpn

RT @UEMSHealthStats: A MASTERMIND study protocol: A trial of a DPP4 inhibitor, SGLT2 inhibitor & thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes. https://t.co/anwDLyFteH @ExeterMed @UofE_Research #healthstatis…

RT @UEMSHealthStats: A MASTERMIND study protocol: A trial of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or thir…

A MASTERMIND study protocol: A trial of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes. https://t.co/YBoZDaN4F9 @ExeterMed @UofE_Research #healthstatistics @BMJ_Open #ExeterD…

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal…

About this Attention Score

Mentioned by

Readers on